New Zealand markets closed
  • NZX 50

    12,541.20
    -40.40 (-0.32%)
     
  • NZD/USD

    0.7094
    +0.0036 (+0.51%)
     
  • NZD/EUR

    0.5904
    +0.0025 (+0.42%)
     
  • ALL ORDS

    7,598.30
    -35.10 (-0.46%)
     
  • ASX 200

    7,356.60
    -29.60 (-0.40%)
     
  • OIL

    72.01
    -0.14 (-0.19%)
     
  • GOLD

    1,819.10
    -42.30 (-2.27%)
     
  • NASDAQ

    13,983.01
    -47.39 (-0.34%)
     
  • FTSE

    7,184.95
    +12.47 (+0.17%)
     
  • Dow Jones

    34,033.67
    -265.63 (-0.77%)
     
  • DAX

    15,710.57
    -18.93 (-0.12%)
     
  • Hang Seng

    28,463.93
    +27.09 (+0.10%)
     
  • NIKKEI 225

    29,014.31
    -276.70 (-0.94%)
     
  • NZD/JPY

    78.4460
    +0.4280 (+0.55%)
     

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

·1-min read

WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

Participants may access a live webcast of the event through the following link:
https://event.on24.com/wcc/r/3173547/7EB680169FF01818435F231AA17B51A2.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting